PolTREG S.A. (PTG) - Net Assets
Based on the latest financial reports, PolTREG S.A. (PTG) has net assets worth zł49.48 Million PLN (≈ $13.62 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł80.19 Million ≈ $22.07 Million USD) and total liabilities (zł30.71 Million ≈ $8.45 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PolTREG S.A. tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł49.48 Million |
| % of Total Assets | 61.7% |
| Annual Growth Rate | 111.9% |
| 5-Year Change | 439.5% |
| 10-Year Change | N/A |
| Growth Volatility | 296.83 |
PolTREG S.A. - Net Assets Trend (2018–2024)
This chart illustrates how PolTREG S.A.'s net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of PolTREG S.A. to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for PolTREG S.A. (2018–2024)
The table below shows the annual net assets of PolTREG S.A. from 2018 to 2024. For live valuation and market cap data, see PolTREG S.A. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł69.23 Million ≈ $19.05 Million |
-20.89% |
| 2023-12-31 | zł87.52 Million ≈ $24.09 Million |
-13.39% |
| 2022-12-31 | zł101.04 Million ≈ $27.81 Million |
-1.91% |
| 2021-12-31 | zł103.01 Million ≈ $28.35 Million |
+702.69% |
| 2020-12-31 | zł12.83 Million ≈ $3.53 Million |
+213983.33% |
| 2019-12-31 | zł-6.00K ≈ $-1.65K |
-100.79% |
| 2018-12-31 | zł764.00K ≈ $210.26K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PolTREG S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4081400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł466.00K | 0.67% |
| Other Comprehensive Income | zł113.18 Million | 163.48% |
| Total Equity | zł69.23 Million | 100.00% |
PolTREG S.A. Competitors by Market Cap
The table below lists competitors of PolTREG S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daesung Eltec Co. Ltd
KQ:025440
|
$24.13 Million |
|
Marti Otel Isletmeleri AS
IS:MARTI
|
$24.14 Million |
|
Giyani Metals Corp
V:EMM
|
$24.15 Million |
|
EDGE TOTAL INTELLIGENCE
F:Q5I
|
$24.15 Million |
|
Choo Bee Metal Industries Bhd
KLSE:5797
|
$24.12 Million |
|
Biotoxtech Co. Ltd
KQ:086040
|
$24.12 Million |
|
Times Guaranty Limited
NSE:TIMESGTY
|
$24.11 Million |
|
Kalyani Forge Limited
NSE:KALYANIFRG
|
$24.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PolTREG S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 87,517,000 to 69,234,000, a change of -18,283,000 (-20.9%).
- Net loss of 18,708,000 reduced equity.
- Other comprehensive income increased equity by 425,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-18.71 Million | -27.02% |
| Other Comprehensive Income | zł425.00K | +0.61% |
| Total Change | zł- | -20.89% |
Book Value vs Market Value Analysis
This analysis compares PolTREG S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 81.97x to 1.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | zł0.23 | zł18.80 | x |
| 2019-12-31 | zł0.00 | zł18.80 | x |
| 2020-12-31 | zł3.85 | zł18.80 | x |
| 2021-12-31 | zł30.16 | zł18.80 | x |
| 2022-12-31 | zł21.67 | zł18.80 | x |
| 2023-12-31 | zł18.77 | zł18.80 | x |
| 2024-12-31 | zł14.85 | zł18.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PolTREG S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5345.14%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.48x
- Recent ROE (-27.02%) is above the historical average (-33.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -176.70% | 0.00% | 0.00x | 13.70x | zł-1.43 Million |
| 2019 | 0.00% | -193.40% | 0.07x | 0.00x | zł-966.40K |
| 2020 | -6.84% | -125.43% | 0.04x | 1.27x | zł-2.16 Million |
| 2021 | -3.63% | -340.13% | 0.01x | 1.06x | zł-14.04 Million |
| 2022 | -1.95% | -196.90% | 0.01x | 1.22x | zł-12.07 Million |
| 2023 | -15.48% | -968.62% | 0.01x | 1.45x | zł-22.30 Million |
| 2024 | -27.02% | -5345.14% | 0.00x | 1.48x | zł-25.63 Million |
Industry Comparison
This section compares PolTREG S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $115,040,487
- Average return on equity (ROE) among peers: -49.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PolTREG S.A. (PTG) | zł49.48 Million | -176.70% | 0.62x | $24.13 Million |
| Bioton S.A. (BIO) | $886.79 Million | 3.00% | 0.74x | $94.05 Million |
| Captor Therapeutics S.A. (CTX) | $96.32 Million | -37.26% | 0.17x | $115.98 Million |
| Mabion S.A. (MAB) | $-54.16 Million | 0.00% | 0.00x | $34.83 Million |
| Molecure S.A. (MOC) | $13.01 Million | -18.64% | 0.19x | $32.21 Million |
| Nanogroup SA (NNG) | $8.37 Million | -119.60% | 1.43x | $20.32 Million |
| Pharmena S.A. (PHR) | $16.45 Million | 3.70% | 0.10x | $9.72 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $18.30 Million | -144.13% | 0.80x | $7.86 Million |
| Ryvu Therapeutics SA (RVU) | $5.53 Million | -116.19% | 1.77x | $90.23 Million |
| Synthaverse S.A. (SVE) | $44.75 Million | -11.87% | 1.10x | $56.30 Million |
About PolTREG S.A.
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland.